ALX Oncology Holdings announced the appointment of Scott Garland to its Board of Directors effective November 29, 2022. Garland is the CEO of PACT Pharma, an immuno-oncology company focused on developing neoantigen targeted T-cell therapies for solid tumors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALXO:
- ALX Oncology Appoints Scott Garland to its Board of Directors
- ALX Oncology price target lowered to $65 from $80 at H.C. Wainwright
- ALX Oncology Announces Upcoming Investor Conference Participation
- ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept
- ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
